

---

# RESPIRI LIMITED

---

## SIGNIFICANT MILESTONE PROGRESS ACHIEVED OVERSEAS

Respiri Limited (ASX: RSH) is pleased to announce that protocols for clinical and real-world studies are being advanced with a number of world-leading institutions as the company executes plans for launch in Q1 2019. CEO, Mario Gattino recently returned from the US and UK with the Non-Executive Chairman, Leon L'Huillier, who as part of the company's management transition, introduced the relevant leading academics, clinicians and scientists with whom Respiri has engaged over the last few years. The overarching objective of this trip and all of our activity over the next few months is focused on accelerating the previously stated major milestones in recent announcements towards a successful launch.

### LEADERS IN DIGITAL MEDICINE RESEARCH, SAN DIEGO

The Scripps Transitional Science Institute (STSI) Division of Digital Medicine is recognised globally for its leadership in the clinical implementation of wireless technologies in healthcare. Investors will no doubt be familiar with the work of Dr Eric Topol, founder and director of STSI and author of bestseller, *'The Patient will See you Now'*. During meetings with the most senior leadership at the institute, our product was recognised as being unique, very promising and with great potential. We believe relationships such as this will shape and formulate our planning for the launch of the product in this very important market.

### KEY OPINION LEADERS & CLINICIANS ON BOARD | UK

The successful launch of the product in the UK requires support from leading academics, clinicians and Key Opinion Leaders (KOLs). There is strong demand for new technologies to help reduce the burden of asthma in the UK and the recent visit confirmed the significant opportunity for Respiri. Following on from our previous visit to the UK in January 2018, the company gained commitments from leading universities and research institutes to perform studies and clinical trials, critical to secure endorsement from the National Health System (NHS) and peak asthma bodies. It should be noted that just as was the case in the US, the new breath sensor design and app were greeted with enthusiasm by all who examined it.

The CEO also met with experienced health sector stakeholder management professionals to map the decision-making landscape in the UK and a member of the House of Lords with a health and social enterprise portfolio who could play an important role in the successful launch of the Respiri product in the UK.

### NEW YORK

The Non-Executive Chairman and CEO also visited the New York based offices of our software and digital platform developer, Two Bulls, to meet with the US based team and share our vision for our platform's smart app focused on the target market of children and young people. As a result, we fast-tracked Executive Producer, Joey Egger's visit to Melbourne this week to commence work on the engagement design. Joey is an Emmy and Peabody award-winning Executive Producer

with over fifteen years of experience producing innovative, engaging and educational multi-platform products with the world's biggest kids' brands including PBS KIDS, Sesame Workshop, Nick Jr, Sprout NBC and Disney. Joey is proving to be an invaluable asset on this project.

A conference call was conducted with one of the largest global diversified technology companies who are market leaders in developing adjacent asthma monitoring products to demonstrate the AirSonea Gen II prototype. Further, a highly informative meeting was held with the founding partner of a leading M&A advisory firm for global mid-market transactions to discuss a range of topics that could support taking the company to the next level and access to future capital.

## **DIGITAL MEDTECH CONFERENCE, SAN FRANCISCO**

On 24 April, 2018, investors received an update from the CEO in a conference call from San Francisco ahead of the Digital Medtech Conference. At this time, the AirSonea Gen II marketing prototype was unveiled and we are pleased to report, the breath sensor design along with the companion app were met with universal approval when demonstrated to industry innovators and academics. The conference sessions confirmed Respiro remains at the forefront of breakthrough asthma monitoring technology with product design that connects to consumers' lives driving adoption and adherence.

It also provided new opportunities for collaboration with industry leaders in key areas including wearables, the optimisation of data using AI, solutions for regulated products and the management of patient programs.

Commenting on the trip, Mario Gattino said, "It was a gruelling three weeks on the road, but I return home inspired and left with no doubt about the opportunities ahead for the AirSonea Gen II and Respiro. When the sharpest and most influential minds in digital connected med-tech and applied asthma research are genuinely excited by the promise of our platform technology and want to be involved in our real-world studies, it is hard to not be fired up. I wish I could share the names and details of everyone we met and how we plan to engage with them, but it is just a little too early in formalising our partnerships to do so. I look forward to sharing this with our shareholders over the coming weeks and months as things fall into place."

The company looks forward to keeping you updated as we achieve each of the stated commercialisation milestones.

-End-

**Contact:**

Mario Gattino  
CEO & Director  
1800 476 632

**About Respi Limited (ASX:RSH)**

Respi is a health technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices. Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respi's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respi has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respi products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun. Respi is especially proud of its recent de-risking of milestones. The substantial achievements over the past 18 months place Respi in a lower risk position and on the cusp of commercialisation compared to the vast majority of medical device and biotech companies

**Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respi only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.